The American Journal of Medicine
Volume 117, Issue 3 , Pages 163-168 , 1 August 2004

Differences in treatment outcome for hepatitis C among ethnic groups

  • Matthew J Hepburn, MD

      Affiliations

    • Department of Medicine (MJH, NSC, MGL, EJL), Brooke Army Medical Center, Fort Sam, Houston, Texas, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Matthew J. Hepburn, MD, U.S. Army Medical Research Institute of Infectious Diseases, MCMR-UIM-R, 1425 Porter Street, Fort Detrick, Maryland 21702-5011, USA
    • ,
  • Lisa M Hepburn, PhD

      Affiliations

    • Harvard School of Public Health (LMH), Boston, Massachusetts, USA
    • ,
  • Norma S Cantu, MD

      Affiliations

    • Department of Medicine (MJH, NSC, MGL, EJL), Brooke Army Medical Center, Fort Sam, Houston, Texas, USA
    • ,
  • Maria G Lapeer, LVN

      Affiliations

    • Department of Medicine (MJH, NSC, MGL, EJL), Brooke Army Medical Center, Fort Sam, Houston, Texas, USA
    • ,
  • Eric J Lawitz, MD

      Affiliations

    • Department of Medicine (MJH, NSC, MGL, EJL), Brooke Army Medical Center, Fort Sam, Houston, Texas, USA

Received 2 July 2003 ,Revised 13 February 2004 ,Accepted 13 February 2004.

References 

  1. National Institutes of Health Consensus Development Conference Panel Statement: management of hepatitis C: 2002–June 10-12, 2002. Hepatology. 2002; 36(suppl):S3–S15.
  2. Alter MJ, Druszon-Moran D, Nainan OV, et al.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556–562
  3. Kim WR. Global epidemiology and burden of hepatitis C. Microbes Infect. 2002;4:1219–1225
  4. Lindsay KL. Introduction to therapy of hepatitis C. Hepatology. 2002;36(suppl):S114–S120
  5. De Maria N, Colantoni A, Idilman R, et al.  Impaired response to high-dose interferon treatment in African Americans with chronic hepatitis C. Hepatogastroenterology. 2002;49:788–792
  6. Howell C, Jeffers L, Hoofnagle JH. Hepatitis C in African Americans (Summary of a workshop). Gastroenterology. 2000;119:1385–1396
  7. Kinzie JL, Naylor PH, Nathani MG, et al.  African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians. J Viral Hepatol. 2001;8:264–269
  8. McHutchison JG, Poynard T, Pianko S, et al.  The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. Gastroenterology. 2000;119:1317–1323
  9. Morelli J, Kim CY, Willner IR. US veterans' experience with Rebetron in a nonstudy environment (Success or failure?). Am J Gastroenterol. 2002;97:2379–2382
  10. Reddy KR, Hoofnagle JH, Tong MJ, et al.  Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology. 1999;30:787–793
  11. Theodore D, Shiffman ML, Sterling RK, et al.  Intensive interferon therapy does not increase virologic response rates in African Americans with chronic hepatitis C. Dig Dis Sci. 2003;48:140–145
  12. Dev AT, McCaw R, Sundararajan V, et al.  Southeast Asian patients with chronic hepatitis C (The impact of novel genotypes and race on treatment outcome). Hepatology. 2002;36:1259–1265
  13. The French METAVIR Cooperative Study Group . Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994;20:15–20
  14. Mallat DB, Jeffers L. The natural history of HCV infection in African Americans. Am J Gastroenterol. 2002;97:520–522
  15. Wiley TE, Brown J, Chan J. Hepatitis C infection in African Americans (Its natural history and histological progression). Am J Gastroenterol. 2002;97:700–706
  16. Bonacini M, Groshen S, Yu MC, et al.  Chronic hepatitis C in ethnic minority patients evaluated in Los Angeles county. Am J Gastroenterol. 2001;96:2438–2441
  17. Thio CL, Thomas DL, Goedert JJ, et al.  Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis. 2001;184:16–21
  18. Kimball P, Elswick RK, Shiffman M. Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-α therapy. J Med Virol. 2001;65:510–516
  19. Sugimoto K, Stadanlick J, Ikeda F, et al.  Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology. 2003;37:590–599
  20. Azocar J, Clavijo OP, Yunis EJ. MHC class II genes in HCV viral clearance of hepatitis C-infected Hispanic patients. Hum Immunol. 2003;64:99–102
  21. Kaufman JS, Cooper RS. Commentary (Considerations for use of racial/ethnic classification in etiologic research). Am J Epidemiol. 2001;154:291–298
  22. Williams DR. Race and health (Basic questions, emerging directions). Ann Epidemiol. 1997;7:322–333
  23. Witzig R. The medicalization of race (Scientific legitimization of a flawed social construct). Ann Intern Med. 1996;125:675–679

☆ Trials were supported by a grant from Schering-Plough Pharmaceuticals, Kenilworth, New Jersey.

PII: S0002-9343(04)00273-6

doi: 10.1016/j.amjmed.2004.02.043

The American Journal of Medicine
Volume 117, Issue 3 , Pages 163-168 , 1 August 2004

Article Tools

* Image Usage & Resolution